IMpassion030

Clinical Trial Program

A phase III, multicenter, randomized, open-label study comparing Atezolizumab (anti-PD-L1 antibody) in combination with adjuvant anthracycline/taxane-based chemotherapy versus chemotherapy alone in patients with operable triple-negative breast cancer.

Phase II, Phase III

Status

Recruiting

Tumour subtype:

TNBC

Scenario

Adjuvant

SPONSOR

F. Hoffmann-La Roche Ltd

COLLABORATORS

Breast International Group (BIG)
Alliance Foundation Trials (AFT).
Institut Jules Bordet/Clinical Trials Support Unit (IJB/CTSU).
Frontier Science Foundation .

PRINCIPAL INVESTIGATORS

Michail Ignatiadis, MD, PhD (Institut Jules Bordet, Université Libre de Bruxelles, Brussels)
Heather McArthur, MD (Cedars Sinai Medical Center Los Angeles, California)

Sites

COMPLEJO HOSPITALARIO HOSPITAL “SAN PEDRO DE ALCANTARA”, HOSPITAL ARNAU DE VILANOVA DE VALENCIA, HOSPITAL CLÍNICO UNIV. LOZANO BLESA, HOSPITAL CLÍNICO UNIV. SANTIAGO DE COMPOSTELA, HOSPITAL DE FUENLABRADA, HOSPITAL DE LEÓN, HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA, HOSPITAL MUTUA DE TERRASSA, HOSPITAL QUIRONSALUD SAGRADO CORAZON, HOSPITAL SON LLATZER, HOSPITAL UNIVERSITARI GENERAL DE CATALUNYA, HOSPITAL UNIVERSITARI SANT JOAN DE REUS, HOSPITAL UNIVERSITARIO 12 DE OCTUBRE, HOSPITAL UNIVERSITARIO DE LA PAZ, HOSPITAL UNIVERSITARIO FUNDACIÓN DE ALCORCÓN, HOSPITAL UNIVERSITARIO INFANTA SOFIA SAN SEBASTIAN DE LOS REYES, HOSPITAL UNIVERSITARIO MADRID SANCHINARRO (CENTRO INTEGRAL ONCOLÓGICO CLARA CAMPAL (CIOCC)), HOSPITAL UNIVERSITARIO VIRGEN DE LA MACARENA, HU PUERTA DE HIERRO DE MAJADAHONDA, HU REY JUAN CARLOS